TranscriptsOct 19, 2026, 7:43 PM ETCytoDyn Inc. (CYDY) StockSA Transcripts162.5K FollowersCytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities October 19, 2026 4:00 PM EDTCompany ParticipantsTyler Blok - Chief Legal Officer & Corporate SecretaryJacob Lalezari - Chief Executive OfficerRobert Hoffman - Chief Financial OfficerConference Call ParticipantsReny AnilinePashtoon Kasi, M.D., M.S.ConversationOperatorGreetings, and welcome to today's CytoDyn Investment Community Webcast. My name is Ignacio Guerrero-Ros, and I will serve as your moderator today. [Operator Instructions] As a reminder, this webcast is being recorded today, October 19, 2026. Following the conclusion of the webcast, a replay will be available for approximately 30 days on the Investor Relations section of the company's website. [Operator Instructions] At the conclusion of today's presentation, the management team will be available to respond to any additional questions. Given the number of questions submitted in advance as well as those we expect to receive during the webcast, we may not be able to address every question today. If your question is not answered today, please, as always, feel free to e-mail your questions to ir@cytodyn.com.I would now like to turn the webcast over to Tyler Blok. You may begin.Tyler BlokChief Legal Officer & Corporate SecretaryGood afternoon, everyone, and thank you for joining us today. Before we begin today's company update, it is essential that we provide you with important cautionary language consistent with certain federal securities laws. Our remarks during today's webcast will include forward-looking statements. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are difficult to predict. Actual results may be materially different from future results expressed or implied by such forward-looking statements.These risks and uncertainties include and relate to, among other things, statements regarding leronlimab's early performance in clinicalRead more current CYDY analysis and newsView all earnings call transcriptsComments